> Detailanzeige

Krug, David; Baumann, René; Krockenberger, Katja; Vonthein, Reinhard; Schreiber, Andreas; Boicev, Alexander; Würschmidt, Florian; Weinstrauch, Evelyn; Eilf, Kirsten; Andreas, Peter; Höller, Ulrike; Dinges, Stefan; Piefel, Karen; Zimmer, Jörg; Dellas, Kathrin; Dunst, Jürgen

Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Adjuvant hypofractionated radiotherapy with simultaneous integrated boost after breast-conserving surgery: results of a prospective trial
  • Beteiligte: Krug, David; Baumann, René; Krockenberger, Katja; Vonthein, Reinhard; Schreiber, Andreas; Boicev, Alexander; Würschmidt, Florian; Weinstrauch, Evelyn; Eilf, Kirsten; Andreas, Peter; Höller, Ulrike; Dinges, Stefan; Piefel, Karen; Zimmer, Jörg; Dellas, Kathrin; Dunst, Jürgen
  • Erschienen: Springer Science and Business Media LLC, 2021
  • Erschienen in: Strahlentherapie und Onkologie
  • Sprache: Englisch
  • DOI: 10.1007/s00066-020-01689-7
  • ISSN: 0179-7158; 1439-099X
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>We report results of a multicenter prospective single-arm phase II trial (ARO-2013-04, NCT01948726) of moderately accelerated hypofractionated radiotherapy with a simultaneous integrated boost (SIB) in patients with breast cancer receiving adjuvant radiotherapy after breast-conserving surgery.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>The eligibility criteria included unifocal breast cancer with an indication for adjuvant radiotherapy to the whole breast and boost radiotherapy to the tumor bed. The whole breast received a dose of 40 Gy and the tumor bed a total dose of 48 Gy in 16 fractions of 2.5 and 3 Gy, respectively. Radiotherapy could be given either as 3D conformal RT (3D-CRT) or as intensity-modulated radiotherapy (IMRT). The study was designed as a prospective single-arm trial to evaluate the acute toxicity of the treatment regimen. The study hypothesis was that the frequency of acute skin reaction grade ≥2 would be 20% or less.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>From November 2013 through July 2014, 149 patients were recruited from 12 participating centers. Six patients were excluded, leaving 143 patients for analysis. Eighty-four patients (58.7%) were treated with 3D-CRT and 59 (41.3%) with IMRT. Adherence to the treatment protocol was high. The rate of grade ≥2 skin toxicity was 14.7% (95% confidence interval 9.8–21.4%). The most frequent grade 3 toxicity (11%) was hot flashes.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>This study demonstrated low toxicity of and high treatment adherence to hypofractionated adjuvant radiotherapy with SIB in a multicenter prospective trial, although the primary hypothesis was not met.</jats:p> </jats:sec>